ClinicalTrials.gg
RecruitingNCT05671718Updated Oct 26, 2026

Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment

An interventional study of Nurse-Led Treatment in Primary Care in Drug Resistant Tuberculosis, sponsored by Johns Hopkins University. Recruiting at 5 sites in South Africa. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,944
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa — 7 open to participants now, 8 under way, 3 of them phase 3. Tuberculosis, Multidrug-Resistant · South Africa.

Planned enrollment
2nd of 37
2,944 · median 248
Started
2023
with 2 others
No phase
8 of 46
5 open now
Registered
42nd of 46
by date
Lead sponsor
2 of 46
Johns Hopkins University

Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, this one is the 2nd largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 42nd registered.

Tuberculosis, Multidrug-Resistant

132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.

Browse Tuberculosis, Multidrug-Resistant studies →

Open to participants now

7 of the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, or all of them as a file.
02

Study summary

The goal of the BringBPaL2Me Trial, a multi-principal investigator, multi-site, cluster randomized, non-inferiority trial is to compare nurse-led RR-TB treatment in primary care clinics to standard of care physician-led RR-TB treatment at district hospitals in the provinces of KwaZulu-Natal, Gauteng, and Eastern Cape.

The main aim is to conduct a 5-year, analyst and clinical safety review committee blinded, multi-site, cluster randomized trial to evaluate 1) treatment outcome; 2) safety; 3) patient associated catastrophic costs with the following hypotheses:

  1. Outpatient nurse-led treatment in PCCs will be non-inferior to outpatient physician-led treatment at hospital-based outpatient sites among RR-TB patients, regardless of HIV co-infection, as determined by a successful treatment outcome [H1].
  2. The proportion of SAEs identified will not significantly differ by blinded, independent review [H2].
  3. Patient associated catastrophic costs (i.e., costs 20% or more of household income) will be lower in nurse-led treatment [H3].
Read the detailed description

In South Africa (SA), nurses manage drug-susceptible Mycobacterium tuberculosis (TB) and TB/HIV coinfection within primary care clinics (PCCs); the TB treatment outcomes in this care model rival the best in the world. A primary care management strategy offers a convenient, patient-centered, model of care that integrates TB and HIV treatment within the same setting. However, a diagnosis of rifampicin-resistant TB (RR-TB), upends this model, requiring referral to a hospital-based, physician-led outpatient treatment center.

Hospital-based models add significant costs to patients, with estimates suggesting more than 80% of RR-TB patients experience catastrophic costs. Such added costs may decrease access to care, delay treatment receipt and contribute to loss to follow-up. One testable solution to this problem, however, is to move RR-TB care to primary care clinics led by nurses. The World Health Organization (WHO) released recommendations for RR-TB treatment earlier this year endorsing 6-month regimens and calling for decentralized, patient-centered models of care closer to the patient's home.

Although SA has long been a leading implementer of nurse-led models of care for TB and HIV due to large physician shortages and the National Department of Health's (NDoH) RR-TB Treatment Guidelines recommend integration of RR-TB within PCCs supporting both physician- and nurse-led models, utilization has been limited. While the team has spent the last decade building observational evidence around outcomes and safety, no randomized controlled trial evaluates nurse-led RR-TB treatment.

Secondary Aims: To evaluate clinical and cost-associated differentiators by arm:

  1. Time to event analysis for a) RR-TB treatment initiation; b) smear/culture conversion; and, as applicable, c) HIV treatment initiation; d) HIV viral suppression; and e) AE and SAE symptom resolution.
  2. Characterization of provider adherence to guidelines for: a) dosing requirements; b) RR-TB dosing changes based on AE and SAE events; and c) AE and SAE adjuvant medication management strategy.
  3. Programmatic cost-effectiveness evaluation.
03

Conditions studied

  • Drug Resistant Tuberculosis

Keywords

  • nurse-led
  • non-inferiority cluster randomized trial
  • primary care
  • drug resistant tuberculosis
  • rifampicin resistant tuberculosis
  • human immunodeficiency virus
  • task sharing
  • South Africa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Cluster Inclusion Criteria:

Primary Care Clinics (PCCs) (i.e., clusters) are eligible if they meet the following:

  1. within one of the selected hospital treatment catchment areas in Kwazulu-Natal, Gauteng and Eastern Cape Provinces;
  2. willingness of provincial TB program managers and hospital leadership to participate;
  3. willingness of PCC nurse manager to participate;
  4. diagnosis of 10 or more RR-TB patients per year; and
  5. have access to necessary labs, X-ray and (ECG) equipment.

Participant Inclusion Criteria:

Adult participants aged 18 years of age and older, regardless of status, who have a new RR-TB diagnosis, deemed willing and able to provide in one of the four most common SA languages [Zulu, Xhosa, Afrikaans, and English] will be eligible.

Participant Exclusion Criteria:

  1. any clinical presentation requiring hospital admission or, in other words, the participant is not a candidate for outpatient primary care initiation (e.g., severe weakness, confusion, severe mental illness, symptomatic low blood pressure, severe shortness of breath, and temp >39.0);
  2. \< 8mg/dL (from National Health Laboratory Service (NHLS) or point of care)) or liver disease ( > 120 U/L);
  3. prolonged >470ms, confirmed by 2 or more ecg;
  4. rapid heartrate, tachycardia (HR >140); confirmed after 5 minutes of rest;
  5. pregnancy;
  6. evidence of extrapulmonary disease;
  7. enrolled in another clinical trial that changes BPaL-L regimen, duration or symptom management process.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
2,944 participants (estimated)

Study arms

  • Experimental
    Nurse-Led Treatment in Primary Care

    At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.

    Other: Nurse-Led Treatment in Primary Care

  • No intervention
    Physician-Led Treatment Hospital Based

    Representing standard of care, primary care clinics will refer to hospital-based, physician-led care who will provide outpatient treatment. The typical clinical operations involve initiation of new patients once or twice weekly and PCCs are required to schedule a clinic day/time for the patient prior to referral (generally \< 72 hours from the time of referral). All individuals receiving care at this site will receive care at the district RR-TB treatment program for the catchment area. For HIV co-infected persons, their HIV treatment is also transferred to the RR-TB physician with details about the HIV treatment communicated in the transfer of care letter. Physicians often cover multiple clinics and routinely take on call sessions on the weekend, due to staffing limitations, thus preventing their sole focus on the RR-TB program and limiting the number of days the RR-TB clinic offers new patient visits and, in most cases, days for follow-up visits.

Interventions

  • OtherNurse-Led Treatment in Primary Care

    At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.

06

What researchers measure

Primary outcomes

  1. RR-TB treatment outcome

    defined by the WHO will include the following: treatment success - the sum of cure and treatment completion; non-success - composite of each of the following negative outcomes: death, for any reason, while enrolled in RR-TB treatment (all-cause mortality); treatment failure - treatment terminated or need for permanent regimen change of at least two drugs because of: lack of culture conversion, bacterial reversion, worsening resistance profile, adverse events; and loss to follow-up interruption of 2 or more consecutive months of missed treatment.

    Time frame: 6 months

  2. Severe Adverse Events as assessed by the Division of AIDS (DAIDS) AE grading table

    The following will be classified as an SAE using the DAIDS AE grading table for the purposes of this protocol: 1. Lab abnormalities demonstrating grade 3 or higher: Myelosuppression (White blood cells (WBC), Red blood cells (RBC), Platelets); hepatotoxicity (Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin); renal impairment (serum creatinine and creatinine clearance) 2. Peripheral neuropathy, grade 3 or higher 3. QT prolongation (Frederica's QTc), grade 3 or higher 4. New onset seizure, regardless of grade 5. Hospitalization, regardless of identified cause 6. Mortality, regardless of identified cause 7. All grade 4 AEs not listed above as an SAE

    Time frame: 12 months

  3. Patient associated catastrophic costs

    (Costs 20% or more of household income) will be lower in nurse-led treatment

    Time frame: 12 months

Secondary outcomes

  1. Time to RR-TB treatment initiation

    Time to event analysis between diagnosis and treatment initiation

    Time frame: 60 days from trial screening

  2. Time to smear/culture conversion

    Time to event analysis between treatment initiation and smear and culture conversion

    Time frame: 120 days after treatment initiation

  3. Time to HIV treatment initiation

    Time to event analysis between enrollment and Antiretroviral therapy (ART) initiation

    Time frame: 120 days after treatment initiation

  4. Time to HIV viral suppression

    Time to event analysis between enrollment and HIV viral load \< 200 copies

    Time frame: 6 months

  5. RR-TB dosing changes based on AE and SAE events

    Provider appropriately manages RR-TB regimen based on AE and SAE events, as determined by blinded safety review

    Time frame: 12 months

  6. Time to adverse (AE) and severe (SAE) treatment related adverse event resolution

    Time to event analysis for adverse and severe treatment related adverse events

    Time frame: 12 months

  7. Time to initiation of HIV prevention

    Time to event analysis between enrollment and HIV prevention initiation for HIV negative patients

    Time frame: 6 months

  8. Provider adherence to dosing requirements, treatment initiation

    Accuracy of regimen dosing based on treatment guidelines

    Time frame: 1 month

  9. AE and SAE adjuvant medication management strategy

    Provider appropriately manages AE and SAE events, as determined by blinded safety review

    Time frame: 12 months

  10. Programmatic cost effectiveness evaluation

    For the health system costs, we will use standard approaches outlined in "Value TB" costing guidelines for TB interventions. If the costs averted are found to be greater than the cost of the nurse-led PCC so that intervention saves money and is non-inferior, then it can be described as dominating (a more effective, less expensive choice) and it is economically the correct choice. In contrast, if the nurse-led PCC is non-inferior and yet more expensive, then we will calculate an incremental cost-effectiveness ratio (i.e., (CostNurse-CostUsual care)/(EffectNurse-EffectUsualCare)) that describes the extra costs necessary for each additional cured case.

    Time frame: 12 months

07

Study locations

5 of 5 sites recruiting
  • Doris Goodwin Hospital
    Pietermaritzburg, KwaZulu-Natal 3201, South Africa
    Recruiting
    • Jason Farley, PhD · Contact
  • Murchison Hospital
    Port Shepstone, KwaZulu-Natal 7007, South Africa
    Recruiting
    • Jason Farley, PhD · Contact
  • King Dinuzulu TB Hospital
    East London, South Africa
    Recruiting
    • Jason Farley, PhD · Contact
  • Nkquebela TB Hospital
    East London, South Africa
    Recruiting
    • Jason Farley, PhD · Contact
  • Jose Pearson Hospital
    Port Elizabeth, South Africa
    Recruiting
    • Jason Farley, PhD · Contact
08

References and documents

Publications

  • van Rensburg C, Berhanu R, Hirasen K, Evans D, Rosen S, Long L. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. PLoS One. 2019 Jun 6;14(6):e0217820. doi: 10.1371/journal.pone.0217820. eCollection 2019. PubMed 31170207 ↗
  • Laurence YV, Griffiths UK, Vassall A. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review. Pharmacoeconomics. 2015 Sep;33(9):939-55. doi: 10.1007/s40273-015-0279-6. PubMed 25939501 ↗
  • Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bull World Health Organ. 2017 Aug 1;95(8):584-593. doi: 10.2471/BLT.17.193375. PubMed 28804170 ↗
  • Masuku SD, Berhanu R, Van Rensburg C, Ndjeka N, Rosen S, Long L, Evans D, Nichols BE. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. Int J Tuberc Lung Dis. 2020 Apr 1;24(4):376-382. doi: 10.5588/ijtld.19.0409. PubMed 32317060 ↗
  • Crowley T, Mokoka E, Geyer N. Ten years of nurse-initiated antiretroviral treatment in South Africa: A narrative review of enablers and barriers. South Afr J HIV Med. 2021 Mar 11;22(1):1196. doi: 10.4102/sajhivmed.v22i1.1196. eCollection 2021. PubMed 33824736 ↗
  • Uebel KE, Fairall LR, van Rensburg DH, Mollentze WF, Bachmann MO, Lewin S, Zwarenstein M, Colvin CJ, Georgeu D, Mayers P, Faris GM, Lombard C, Bateman ED. Task shifting and integration of HIV care into primary care in South Africa: the development and content of the streamlining tasks and roles to expand treatment and care for HIV (STRETCH) intervention. Implement Sci. 2011 Aug 2;6:86. doi: 10.1186/1748-5908-6-86. PubMed 21810242 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Jun 2028, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 5, 2023
StartActual
Sep 4, 2023
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05671718
Collaborators
University of Witwatersrand, South Africa, University of Cape Town, National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party
Sponsor
First posted
Jan 5, 2023
Start date
Sep 4, 2023
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Kelly Lowensen, MSN, RN
Contact
klowens1@jhu.edu
4104091372
Jason Farley, PhD, MPH, ANP-BC
principal investigator · The Center for Infectious Disease and Nursing Innovation (CIDNI)
Denise Evans, PhD
principal investigator · University of Witwatersrand, South Africa
Norbert Ndjeka, MBChB
principal investigator · University of Cape Town

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion